143 related articles for article (PubMed ID: 36913542)
1. Use of SGLT2 Inhibitors Reduces Heart Failure and Hospitalization: A Multicenter, Real-World Evidence Study.
Blanco CA; Garcia K; Singson A; Smith WR
Perm J; 2023 Mar; 27(1):77-87. PubMed ID: 36913542
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.
Zelniker TA; Wiviott SD; Raz I; Im K; Goodrich EL; Furtado RHM; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Sabatine MS
Circulation; 2019 Apr; 139(17):2022-2031. PubMed ID: 30786725
[TBL] [Abstract][Full Text] [Related]
3. Real-World Prescription Patterns and Barriers Related to the Use of Sodium-Glucose Cotransporter 2 Inhibitors among Korean Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease.
Baek JH; Yang YS; Ko SH; Han KD; Kim JH; Moon MK; Park JS; Lee BW; Oh TJ; Chon S; Choi JH; Hur KY
Diabetes Metab J; 2022 Sep; 46(5):701-712. PubMed ID: 35654585
[TBL] [Abstract][Full Text] [Related]
4. Decrease of coronary heart disease risk with GLP1-receptor agonists or SGLT2 inhibitors therapy in patients with type 2 diabetes in primary cardiovascular prevention: A 24 months follow-up study.
D'Onofrio L; Mignogna C; Carlone A; Bellizzi E; Di Guida M; Moretti C; Zampetti S; Leto G; Maddaloni E; Buzzetti R
Diabetes Res Clin Pract; 2021 Mar; 173():108681. PubMed ID: 33516784
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular Outcomes and Risks After Initiation of a Sodium Glucose Cotransporter 2 Inhibitor: Results From the EASEL Population-Based Cohort Study (Evidence for Cardiovascular Outcomes With Sodium Glucose Cotransporter 2 Inhibitors in the Real World).
Udell JA; Yuan Z; Rush T; Sicignano NM; Galitz M; Rosenthal N
Circulation; 2018 Apr; 137(14):1450-1459. PubMed ID: 29133607
[TBL] [Abstract][Full Text] [Related]
6. A review of glucagon-like peptide 1 receptor agonist and sodium-glucose cotransporter 2 inhibitor cardiovascular trials: Implications for practice.
Battise DM; Olin JL
J Am Assoc Nurse Pract; 2021 Mar; 33(12):1139-1147. PubMed ID: 33105320
[TBL] [Abstract][Full Text] [Related]
7. Comparing benefits from sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in randomized clinical trials: a network meta-analysis.
Sabouret P; Bocchino PP; Angelini F; D'Ascenzo F; Galati G; Fysekidis M; DE Ferrari GM; Fischman DL; Bhatt DL; Biondi-Zoccai G
Minerva Cardiol Angiol; 2023 Apr; 71(2):199-207. PubMed ID: 35195376
[TBL] [Abstract][Full Text] [Related]
8. Comparison of cardiovascular outcomes of new antihyperglycemic agents in Type 2 Diabetes Mellitus: a meta-analysis.
Zhou Z; Zheng M; Zuo Z; Wu T
ESC Heart Fail; 2024 Jun; 11(3):1647-1656. PubMed ID: 38419382
[TBL] [Abstract][Full Text] [Related]
9. Comparative effectiveness of SGLT2i versus GLP1-RA on cardiovascular outcomes in routine clinical practice.
Fu EL; Clase CM; Janse RJ; Lindholm B; Dekker FW; Jardine MJ; Carrero JJ
Int J Cardiol; 2022 Apr; 352():172-179. PubMed ID: 35074492
[TBL] [Abstract][Full Text] [Related]
10. Differential cardiovascular and renal benefits of SGLT2 inhibitors and GLP1 receptor agonists in patients with type 2 diabetes mellitus.
Kim CH; Hwang IC; Choi HM; Ahn CH; Yoon YE; Cho GY
Int J Cardiol; 2022 Oct; 364():104-111. PubMed ID: 35716949
[TBL] [Abstract][Full Text] [Related]
11. Association of Prescription Co-payment With Adherence to Glucagon-Like Peptide-1 Receptor Agonist and Sodium-Glucose Cotransporter-2 Inhibitor Therapies in Patients With Heart Failure and Diabetes.
Essien UR; Singh B; Swabe G; Johnson AE; Eberly LA; Wadhera RK; Breathett K; Vaduganathan M; Magnani JW
JAMA Netw Open; 2023 Jun; 6(6):e2316290. PubMed ID: 37261826
[TBL] [Abstract][Full Text] [Related]
12. Bridging the gap in cardiovascular care in diabetic patients: are cardioprotective antihyperglycemic agents underutilized?
Scheen AJ
Expert Rev Clin Pharmacol; 2023; 16(11):1053-1062. PubMed ID: 37919944
[TBL] [Abstract][Full Text] [Related]
13. Clinical potential relevance of metabolic properties of SGLT2 inhibitors in patients with heart failure.
Galli M; D'Amario D; Sofia C; Vaccarella M; Crea F; Aspromonte N
Expert Opin Drug Metab Toxicol; 2018 Dec; 14(12):1273-1285. PubMed ID: 30472914
[No Abstract] [Full Text] [Related]
14. Primary Prevention of Cardiovascular and Heart Failure Events With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Their Combination in Type 2 Diabetes.
Wright AK; Carr MJ; Kontopantelis E; Leelarathna L; Thabit H; Emsley R; Buchan I; Mamas MA; van Staa TP; Sattar N; Ashcroft DM; Rutter MK
Diabetes Care; 2022 Apr; 45(4):909-918. PubMed ID: 35100355
[TBL] [Abstract][Full Text] [Related]
15. Prevention of heart failure events with sodium-glucose co-transporter 2 inhibitors across a spectrum of cardio-renal-metabolic risk.
Bhatia K; Jain V; Gupta K; Bansal A; Fox A; Qamar A; Damman K; Vaduganathan M
Eur J Heart Fail; 2021 Jun; 23(6):1002-1008. PubMed ID: 33609071
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of Continuing SGLT2 Inhibitors on Outcomes in Patients with Acute Decompensated Heart Failure.
Nakagaito M; Imamura T; Joho S; Ushijima R; Nakamura M; Kinugawa K
Int Heart J; 2021 Jul; 62(4):885-890. PubMed ID: 34276019
[TBL] [Abstract][Full Text] [Related]
17. Sodium-glucose cotransporter 2 inhibitors and heart failure: the best timing for the right patient.
Severino P; D'Amato A; Prosperi S; Costi B; Angotti D; Birtolo LI; Chimenti C; Lavalle C; Maestrini V; Mancone M; Fedele F
Heart Fail Rev; 2023 May; 28(3):709-721. PubMed ID: 34654997
[TBL] [Abstract][Full Text] [Related]
18. The Role of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Heart Failure, Regardless of Diabetes Status: Focus on Cardiovascular Disease.
Ferrari F; Martins VM; Scheffel RS; da Silveira AD; Motta MT; Moriguchi EH; Santos RD; Stein R
Ann Pharmacother; 2021 Oct; 55(10):1267-1275. PubMed ID: 33401940
[TBL] [Abstract][Full Text] [Related]
19. Underuse of cardiorenal protective agents in high-risk diabetes patients in primary care: a cross-sectional study.
Hao R; Myroniuk T; McGuckin T; Manca D; Campbell-Scherer D; Lau D; Yeung RO
BMC Prim Care; 2022 May; 23(1):124. PubMed ID: 35606699
[TBL] [Abstract][Full Text] [Related]
20. Sodium-glucose cotransporter-2 inhibitors and risk for genitourinary infections in older adults with type 2 diabetes.
Varshney N; Billups SJ; Saseen JJ; Fixen CW
Ther Adv Drug Saf; 2021; 12():2042098621997703. PubMed ID: 33854754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
